BioShai

Company Overview

Snapshot

Founded in January 2014 by Martin Rabey, BioShai operates with 1–10 employees. The company has secured funding across two rounds from Youdim Pharmaceuticals. A notable milestone for BioShai was the development of the world's first blood test to aid in the diagnosis of Parkinson's disease.

Business overview

BioShai develops PDx, a blood test designed for the early diagnosis of Parkinson's disease. This diagnostic tool measures the expression levels of a specific set of genes, which can be integrated with other clinical data to provide a comprehensive diagnosis and guide treatment decisions. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Test Diagnostics & Screening, serving healthcare providers and laboratories.

Strategic signal

In November 2016, BioShai announced the development of the world's first blood test to aid in the diagnosis of Parkinson's disease. This breakthrough signifies a major advancement in early detection capabilities for a complex neurological disorder, potentially enabling earlier intervention and improved patient outcomes. For investors, this highlights BioShai's innovative approach in the diagnostics space and its potential to address significant unmet medical needs.

Company Intelligence Q&A

What is BioShai's primary focus?

BioShai is focused on developing PDx, a blood test for the early diagnosis of Parkinson's disease, based on measuring gene expression levels.

When was BioShai founded?

BioShai was founded in January 2014.

Who is a co-founder of BioShai?

Martin Rabey is a co-founder and CMO of BioShai.

What significant product was announced by BioShai?

In November 2016, BioShai announced the world's first blood test to aid in the diagnosis of Parkinson's disease.

Which organization provided non-equity funding to BioShai?

In January 2015, BioShai received non-equity funding from the Michael J. Fox Foundation.